

FRA2 Is a STAT5 Target Gene Regulated by IL-2 in Human CD4 T Cells

Aradhana Rani¹, Roseanna Greenlaw¹, Manohursingh Runglall¹, Stipo Jurcevic^{1*}, Susan John^{2*}

1 Division of Transplantation Immunology and Mucosal Biology, King's College London, London, United Kingdom, **2** Department of Immunobiology, King's College London, London, United Kingdom

Abstract

Signal transducers and activators of transcription 5(STAT5) are cytokine induced signaling proteins, which regulate key immunological processes, such as tolerance induction, maintenance of homeostasis, and CD4 T-effector cell differentiation. In this study, transcriptional targets of STAT5 in CD4 T cells were studied by Chromatin Immunoprecipitation (ChIP). Genomic mapping of the sites cloned and identified in this study revealed the striking observation that the majority of STAT5-binding sites mapped to intergenic (>50 kb upstream) or intronic, rather than promoter proximal regions. Of the 105 STAT5 responsive binding sites identified, 94% contained the canonical (IFN- γ activation site) GAS motifs. A number of putative target genes identified here are associated with tumor biology. Here, we identified Fos-related antigen 2 (FRA2) as a transcriptional target of IL-2 regulated STAT5. FRA2 is a basic -leucine zipper (bZIP) motif 'Fos' family transcription factor that is part of the AP-1 transcription factor complex and is also known to play a critical role in the progression of human tumours and more recently as a determinant of T cell plasticity. The binding site mapped to an internal intron within the FRA2 gene. The epigenetic architecture of FRA2, characterizes a transcriptionally active promoter as indicated by enrichment for histone methylation marks H3K4me1, H3K4me2, H3K4me3, and transcription/elongation associated marks H2BK5me1 and H4K20me1. FRA2 is regulated by IL-2 in activated CD4 T cells. Consistently, STAT5 bound to GAS sequence in the internal intron of FRA2 and reporter gene assays confirmed IL-2 induced STAT5 binding and transcriptional activation. Furthermore, addition of JAK3 inhibitor (R333) or Daclizumab inhibited the induction in TCR stimulated cells. Taken together, our data suggest that FRA2 is a novel STAT5 target gene, regulated by IL-2 in activated CD4 T cells.

Citation: Rani A, Greenlaw R, Runglall M, Jurcevic S, John S (2014) FRA2 Is a STAT5 Target Gene Regulated by IL-2 in Human CD4 T Cells. PLoS ONE 9(2): e90370. doi:10.1371/journal.pone.0090370

Editor: Thomas Langmann, University of Cologne, Germany

Received: October 22, 2013; **Accepted:** January 29, 2014; **Published:** February 28, 2014

Copyright: © 2014 Rani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors would like to acknowledge the support of the MRC Centre for Transplantation. This work was supported by Wellcome Trust UK Grant 074656/Z/04/Z (to S.John). The research was funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: stipo.jurcevic@kcl.ac.uk (SJurcevic); susan.john@kcl.ac.uk (SJohn)

Introduction

Signal transducers and activators of transcription STAT5a and STAT5b (collectively called STAT5) are highly homologous proteins that are encoded by two separate genes and are activated by Janus-activated kinases (JAK) downstream of cytokine receptors. STAT proteins are activated by a wide variety of cytokines, all of which use the JAK-STAT signalling pathway as their main mode of signal transduction [1]. Upon activation by cognate JAKs, STAT proteins, dimerize and translocate into the nucleus where they bind to the promoters of genes containing the consensus recognition motif (GAS motif-TTCN₃GAA) resulting in the transcriptional regulation of target genes.

Several studies have shown that STAT5 proteins regulate multiple genes primarily involved in T cell survival, proliferation, differentiation and homeostasis, either by transcriptional activation or repression by recruitment of negative regulatory cofactors [2]. Given its critical role in vital cellular processes, major efforts have been made to identify direct cellular targets of STAT5 using techniques such as ChIP-chip and ChIP-seq techniques [3,4,5]. However, the target genes identified by STAT5-ChIP differ between cell types and are further influenced by cell treatments

and time points studied [6,7]. Thus, the range of target genes that STAT5 regulates may differ from one cell to another, from one cell treatment to another as well as being dependant on the time point studied. Nevertheless, these studies have begun to provide important mechanistic insights into the regulation of various biological and cellular processes by STAT5.

In this study, we aimed to identify genes regulated by IL-2/STAT5 in preactivated CD4 T cells by ChIP, with a view to understanding the range of STAT5 target genes and the molecular actions regulated by IL-2 in this cell type. Analysis of the target sites provided an insight at various levels, such as relative positioning with respect to the transcription start site (TSS) of genes, with only a small percentage (11%) within 10 kb of the TSS of gene/s; presence/absence of GAS sequences, which revealed that 94% contained the consensus/non-consensus recognition motif; epigenetic changes associated with mapped sites; identification of putative downstream-target genes and hence the potential cellular processes and biological pathways that may be regulated by STAT5.

Previously, it was shown that IL-2 and STAT5 plays a prominent role in human and murine TH2 cell differentiation and we recently showed that *c-maf* is an IL-2 induced STAT5

target gene that is involved in this process [4,8,9,10]. In keeping with the Th2 theme for IL-2/STAT5, here we present the characterization of the FRA2 as a STAT5 target gene, identified from the ChIP cloning studies. In the immune system, FRA2 is involved in IL-4 gene regulation and is involved in CD4-Th2 cell differentiation [11]. More recently, FRA2 has been documented as a key determinant of cellular plasticity during CD4 T cell differentiation [12]. FRA2 is a member of the FOS/JUN subgroup of bZIP transcription factors (TFs) and the AP1 transcription factor complex, which consists of heterodimers formed by the Fos family (c-FOS, FOSB, FRA1, and FRA2) with Jun family (c-JUN, JUNB and JUND) of transcription factors [13,14]. AP1 complexes are able to activate or suppress the expression of many genes involved with proliferation, differentiation, and survival: functions in common with STAT5. Consistent with its role in vital cellular functions, dysregulated expression of FRA2 has also been associated with lymphomas [15].

In this study, we identify one of the ChIP-cloned sequences to map to an internal intronic region of the FRA2 gene, and show that *FRA2* is induced by T-cell receptor activation in human CD4 T cells in an IL-2/JAK3/STAT5 dependent manner.

Materials and Methods

Human blood CD4 T cell isolation and culture conditions

PBMCs were isolated by density gradient centrifugation from heparinized buffy coat obtained from the National Blood Service (St. George's Hospital, London). CD4 T cells were isolated by positive selection from the PBMCs using CD4 microbeads and (Miltenyi Biotec, Auburn, CA) an LS column as described in the manufacturer's instructions. Cells were maintained in RPMI 1640 medium (PAA Laboratories, Yeovil, UK) with 10% fetal bovine serum (FBS, PAA laboratories), 2 mM L-glutamine and penicillin-streptomycin (100 IU/ml and 100 µg/ml, Sigma-Aldrich, UK). The freshly isolated CD4 T cells were either used immediately or activated with PHA 2 µg/ml (EY Laboratories, San Mateo, CA) for 72 hours to generate PHA blasts. The PHA blasts were rested for 16 hours in complete RPMI 1640 medium before restimulation. Where appropriate, cells were stimulated with 100 U/ml IL-2 (TECIN, [Teceleukin]; Roche) for 20 minutes or as stated for activation kinetics experiments. In other experiments, CD4 T cells were activated with plate bound anti-CD3 (UCHT1; 10 µg/ml) and soluble anti-CD28 Ab (2 µg/ml; Ancell, Bayport, MN) with or without the JAK3 inhibitor R333 (5 µM; a gift from Rigel Pharmaceuticals, South San Francisco) or humanized anti-Tac (HAT, or Daclizumab (Zenapax), 10 µg/ml, Roche, Nutley, NJ).

Chromatin Immunoprecipitation, Cloning and Sequencing

Chromatin immunoprecipitation (ChIP) cloning experiments were performed using 1.5×10^7 CD4 T cells stimulated with IL-2 for 20 min followed by a 10-min crosslink with formaldehyde (0.37%) at 37°C and immediate termination of the reaction by the addition of 1.25 M glycine, as previously described [6]. The cells were harvested and shearing of the chromatin was done on a Misonix 3000 sonicator. The sonicated chromatin was immunoprecipitated for an hour using µMACS protein A microbeads (Miltenyi Biotec, UK) and anti-STAT5a and -STAT5b monoclonal antibodies or control mouse IgG Abs (all from Zymed Laboratories, UK). Purified chromatin was blunt-end repaired using T4 DNA polymerase (New England Biolabs, UK), ligated to linkers, PCR amplified, and cloned into TOPO vector (Invitrogen, UK) and sequenced (Cogenics, UK). Validation and confirmation of the GAS sequence within the *FRA2* gene, as a STAT5 target

was done by quantitative PCR reaction, performed as described in the LowCell# ChIP Kit TM (Diagenode, UK) and data interpreted as a percentage of the starting material (Input).

In silico mapping and screening of cloned sequences

Individual clones were blasted against the UCSC Genome Browser (<http://genome.ucsc.edu>) and the public databases at NCBI using the BLAST tool (<http://www.ncbi.nlm.nih.gov/>) and filtered for 100% identity.

The sequences were screened for closest genes and conservation tracks using the March 2006 (hg 18) human reference sequence (NCBI Build 36.1). Additionally, the sequences were mapped to the whole genome analysis of DNase-I Hypersensitivity sites in CD4 T-cells using the May 2004 (hg17) human reference sequence (NCBI Build 35) [16]. Gene ontology analyses of all the cloned sequences were performed using the PANTHER database [17].

RNA isolation, cDNA synthesis and RT-PCR

Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies, CA, USA). 500 ng of total RNA was reverse-transcribed to cDNA using the TaqMan Reverse Transcription kit (Life Technologies) following manufacturer's instructions. The first-strand cDNA obtained using the above protocol was amplified using different primer/probe mix in 384-well plates using the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). The sequence detector SDS 2.3 software (Applied Biosystems) was used to export the Ct values. 18S gene expression was used as the endogenous reference gene. Quantification was done by applying the following equation: $RQ = 2^{-\Delta Ct}$ where RQ represents the estimated amplification assuming a doubling of material during each PCR cycle and ΔCt is the $Ct(\text{gene}) - Ct(18\text{ s})$ and Ct is the cycle at which the threshold is crossed.

Cell transfection and luciferase reporter assays

HEK293T cells were transfected to reconstitute IL-2R signaling using the calcium phosphate method, as previously described [18]. Trimerized GAS1 sequence was synthesized (Sigma, UK), cloned into pGL4.23 (luc2/minP) vector (Promega, UK), and verified by sequencing (Eurofins MWG-Operon, Germany). 2 µg of IL-2 receptor β chain, 0.5 µg of common cytokine receptor γ chain, 0.25 µg of JAK3, and 75 ng of each of the Stat5 plasmids, 0.5 ng of the control pTK-Renilla Luciferase plasmid and 1 µg of the reporter plasmids were cotransfected into 293 T cells. After 24 hours, cells were treated with 100 IU of IL-2 overnight and assayed for luciferase activity. Luciferase assays were performed by using the Dual-Glo luciferase kit (Promega, UK) according to the manufacturer's instructions. To normalize for transfection efficiency, luciferase activity was divided by the Renilla luciferase activity, which gave a relative luciferase activity for each sample. Further, the IL-2 induced value is divided by the uninduced value to give a fold induction.

Results and Discussion

Identification of STAT5 regulated genes

In vivo STAT5 targets in human activated CD4 T cells were identified by ChIP, followed by cloning and sequencing. A total of 105 unique binding sites were mapped and assigned to the genome (Table S1). The genomic distribution of STAT5 binding sites were analysed with respect to an annotated gene as being present within introns, or, <10 kb upstream of the gene and in intergenic regions (here defined as regions >10 kb from the 5' end of the two closest

annotated genes on a chromosome). Thus, for STAT5 target sites located <10 kb upstream of a gene, the closest gene was considered as a potential regulatory target. For fragments mapping to an intron, the corresponding gene was designated the potential STAT5 target gene and for intergenic binding sites, both the genes involved were considered as potential targets.

Of the 105 unique cloned inserts isolated from activated CD4 T cells, greater than one third (42%) of the fragments lie within introns of annotated genes, with a larger percentage within intron 1 (13%). A significant number of binding sites (49, 47%) correspond to intergenic regions, while 12 of the fragments (11%) were within 10 kb upstream of a gene (Figure 1). These findings predict that generally STAT5 binds within enhancer rather than promoter regions and facilitates transcription through long distance interactions by DNA looping [19]. ChIP-seq studies on STAT1 and NF- κ B are consistent with these findings and demonstrate that the percentage of binding sites in intergenic or intronic regions far exceeds those in the promoters of genes [20,21]. Studies of other transcription factors have shown that binding sites can be as far as 168 kb and 206 kb upstream of a transcription start site [22].

Further, an *in silico* analysis of the clones was performed to investigate the presence of STAT5 recognition motifs TTCN₃GAA and TTN₅AA. The consensus GAS recognition motif for dimeric STAT5 binding is TTCN₃GAA [23]. However, STAT5 can also potentially recognize the more general consensus TTN₅AA, when it binds DNA as a tetrameric complex of N-domain linked dimers [23]. The motifs were subdivided into three groups: clones containing TTCN₃GAA sites, clones containing TTN₅AA sites and those containing no GAS motifs. The results are summarized as a pie-chart in Figure 2. The striking observation for this analysis was that the majority of the sequences contained the more general TTN₅AA sequence, rather than the consensus GAS motif, TTCN₃GAA, perhaps indicating a less stringent requirement for DNA recognition, reminiscent of DNA binding by tetrameric STAT5 complexes. Several clones had multiple GAS motifs of either type. In view of this observation, it is interesting to note previous studies that have shown strengthening by virtue of the protein-protein interactions mediated via the N-domains, whereby tetrameric STAT5 complexes can specifically bind to tandem-linked non-consensus or non-GAS motifs in

addition to consensus GAS motifs, thus increasing the repertoire of STAT5-regulated genes [18]. Two other STAT5-ChIP-cloning studies have also observed use of only the TTN₅AA sequences [7], while studies of other transcription factors have noted the use of similar non-consensus recognition motifs [24]. These findings are consistent with the recent demonstration that the STAT5 tetramer plays a critical role in the cytokine responses of normal immune function and in the resistance to malignant transformation of cells [25,26]. Consistent with previous observations from in-vitro STAT5 binding studies, a small number of the putative STAT5-binding sites did not contain a recognizable GAS motif (23). Similar results have been obtained for other transcription factors and other STAT5-ChIP studies where it was observed that the frequency of factors not binding to consensus sequences was very high [24]. Taken together, STAT5 appears to favor the less stringent general consensus GAS motif, for *in-vivo* DNA binding, which would potentially be bound by tetrameric STAT5.

Although an in-silico analysis of the target binding sites enhanced our knowledge of potential STAT5-regulated genes, they are in need of experimental validations and functional studies. Verification of the robustness of the ChIP assay was confirmed by independent ChIP-PCR analysis on the target sites which demonstrated that they were bonafide STAT5 binding sites.

Although the genes associated with the putative STAT5 binding sites have not all been confirmed as being bonafide STAT5 regulated genes, they were classified into functional categories to gain insight into the cellular functions that could potentially be regulated by STAT5 in activated CD4+ T cells. One important caveat to this analysis is that, where a particular binding site could not be annotated to a single gene, as in the case of intergenic sites, both flanking genes were considered in the functional classification. They were categorized using the PANTHER database (Figure 3A and 3B). The functional categories predicted from this analysis included metabolic, cellular, cell communication, developmental, immune system, cell cycle, transport and apoptosis. While many of the predicted functions from this analysis are consistent with known functions of STAT5, for instance cell cycle, differentiation, survival, signal transduction, others such as cell adhesion, transport and metabolism are novel functions predicted from this study.

The molecular functional categories of target sites that were most highly represented in activated CD4+ T cells were genes




Figure 1. The locations of putative STAT5 binding sites in activated CD4+ T cells. Mapping of STAT5 binding sites relative to annotated genes were categorized into four groups. Intergenic region denotes binding sites present greater than 10 kb away from both flanking genes. <10 kb upstream denotes the region less than 10 kb upstream of the 5' region of the nearest gene. Internal intron denotes introns other than intron 1 of the gene and intron 1 depicts the presence of a binding site within the first intron of the gene.
doi:10.1371/journal.pone.0090370.g001




Figure 2. STAT5 motif analysis of the mapped ChIP clones in activated CD4+ T cells. Out of the 105 binding sites for activated CD4+ T cells immunoprecipitated with anti-STAT5 Ab, 68% had TTN₅AA motifs and TTCN₃GAA sites were present in 26% of the target sites. The labels denote the category name and percentage.
doi:10.1371/journal.pone.0090370.g002




Figure 3. Gene ontologies of putative STAT5 targets from activated CD4+T cells. Gene function of putative binding sites is based on the summary information provided in the PANTHER database. Out of the 105 binding sites identified, functional categorisation was done for 104 genes, out of which 99 could be classified and the remaining 5 genes were of unknown/uncategorized function. Those 99 genes were classified based on their molecular function (A) and biological processes (B). In some instances, a given gene was represented in more than one category (for example, FRA2 was incorporated under the binding (GO:0005488) as well as transcriptional regulator activity (GO: 0030528) molecular functions). doi:10.1371/journal.pone.0090370.g003

encoding binding, catalytic activity, receptors, transcription, enzymes and proteins involved in cell differentiation, proliferation and survival. Consistent with the known association of aberrant constitutive activation of STAT5 with human cancers/tumours of haematological and non-haematological origins, several potential oncogenes were identified as putative downstream target genes. These include, *TLE4* [27], *ACSL6* [28], *TOPI* [28], *TCEA1*, *TSC22D1*[29], *KIF1A* [30], *HERC2*[30], *LRP1B* [31], *CDH10* [32,33], *ST6GAL2*[32], *FAT1*[33], *CHD1*[34], *GRID1*[35,36], *IGFBP3*[35], *ADAM22*[37], *CHD6* [38] and *FRA2* [15]. Thus, the functional classification of potential STAT5-regulated genes confirmed known functions of STAT5 and furthermore provided novel insight into potential unknown cellular functions and oncogenes regulated by these proteins. Of these, we chose to further characterize FRA2 in this study, as this gene seemed

particularly interesting in light of the fact that FRA2 is not only associated with malignant transformation, but is also a key regulator of CD4 T cell differentiation, both of which are known activities of STAT5 [11,15].

Interestingly, *FRA2* was also identified in a STAT5-ChIP study from IL-3 stimulated BAF3 cells, suggesting that it is an important downstream mediator of STAT5 function, irrespective of the activating cytokine [39].

In Silico analysis of FRA2 locus in CD4+ T cells

The cloned sequence that mapped to an internal intron within the *FRA2* gene contained a consensus GAS sequence, TTCTGAGAA and one other TTN₅AA sequence: TTGGAGCAA (GAS1, Figure 4A).




Figure 4. Study of the binding site, location and validation of the cloned fragment obtained by ChIP. A. Sequence of the cloned fragment and the corresponding typical and atypical GAS sequences present. There is a TTN₅AA (blue font) sequence and one typical GAS TTCN₃GAA (red font) sequence present within the cloned fragment. B. The relative location of the cloned fragment, GAS1 and GAS2 with respect to the FRA2 transcription start site (TSS) and intron/exon is shown schematically and its coordinates on the UCSC genome browser. Figure 4C: IL-2 induces in-vivo binding of STAT5 to GAS1 within the third intron of the FRA2 gene in preactivated CD4 T cells. STAT5-ChIP samples from \pm IL-2-treated preactivated CD4 T cells were analysed by real-time PCR for specific binding to the two GAS motifs identified above. ChIP assay was performed using the LowCell# ChIP kit and \pm IL-2-treated preactivated CD4 T cells. Enrichment of GAS 1 was higher when compared to GAS 2 and more so with the STAT5b antibody.
doi:10.1371/journal.pone.0090370.g004

To further explore the mechanism of *FRA2* regulation by STAT5, the 5' upstream regulatory region was scanned for GAS sequences located either within or near to hypersensitive sites, identified by the CD4 DHS study [40]. One additional DHS site was identified, which contained a GAS motif (GAS2). A schematic figure representing the GAS sequences studied is shown (Figure 4B). While GAS1 represents the sequence present within the identified clone in intron 3 of the FRA2 gene, GAS2 represents the scanned GAS sequence present within the 5' TSS. GAS 1 mapped to chromosome 2 at +17850 to +18554 bp (Intron 3) and

GAS2 mapped to chromosome 2 at -3108 to -2820 bp upstream (TSS) of the FRA2 gene, both of which contained a consensus GAS motif.

To determine whether the *FRA2* GAS (GAS1 and GAS2) sequences within the cloned site and promoter region are direct targets of STAT5, quantitative real-time ChIP-PCR was performed on chromatin obtained by ChIP of IL-2-stimulated (or untreated control) PHA-activated human CD4 T cells. Specific primers encompassing the GAS fragments were used and the ChIP was performed using an anti-STAT5 antibody or IgG




Figure 5. Custom Track View of DNase I hypersensitive sites (DHS) sites. DHS sites, Pol II, H3K20me1, H3K4me3, H3K4me2, H3K4me1, H2BK5me1 and H2A.Z along the *FRA2* gene on Chr 2 were obtained from the UCSC Genome Browser.
doi:10.1371/journal.pone.0090370.g005

control. Enrichment of both GAS1 and GAS2 was observed, although the binding specificity was noticeably higher for the cloned GAS1 site, which also shows a greater enrichment for STAT5b as compared to STAT5a (Figure 4C). Enrichment of the STAT5 binding site was observed for chromatin that was immunoprecipitated with STAT5a and STAT5b antibody in the presence of IL-2 when compared to unstimulated and IgG control.

Thus, IL-2 induces specific binding enrichment of STAT5b primarily to a region in the intron of the *FRA2* locus.

The *FRA2* cloned fragment, when queried for its location with respect to the genome-wide DNase HS (DHS) sites in CD4+ T cells (UCSC Genome Browser on Human May 2004 Assembly, hg17) [40], demonstrated that it is located within a DNase hypersensitive site. Genome wide studies into histone modifications by acetylation and methylation on CD4 T cells has provided




Figure 6. IL-2 regulates expression of FRA2. Quantitative RT-PCR was performed on PHA activated CD4+ T cells stimulated with or without IL-2 for different times to evaluate the expression of FRA2. Expression levels are presented as fold increase (logarithmic scale) and compared to the baseline levels (cells not treated with IL-2). 18 s was used as the housekeeping gene and served as the endogenous control. IL-2 stimulation strongly induced *FRA2* expression with two peaks observed at 4–6 hours and 24 hours post stimulation. This is representative of at least three independent experiments performed in triplicate.

doi:10.1371/journal.pone.0090370.g006

valuable insights into the activation, repression or silencing of genes in these cells [41,42]. Acetylation of histones, which is invariably associated with gene activation, is regulated by various methylations (position and state) of the lysine and arginine residues on histone tails to dictate either an activation or repression of genes [43,44,45]. Some of the methylation marks associated with activation are H2BK5me1, H3K4me1, H3K4me2, H3K4me3, and H4K20me1. A study of the methylation pattern available on the UCSC genome browser also suggests *FRA2* is a transcriptionally active gene in CD4+ T cells (Figure 5). The *FRA2* gene also contains regions of enrichment of the H2 variant, H2A.Z, which is often associated with nucleosome instability (Figure 5)(43). This would indicate that the chromatin in the *FRA2* locus is transcriptionally active, because the GAS motifs are located within DHSs [40]. Thus, this locus appears to be “poised” for transcriptional activation in unactivated CD4 T cells.

Mining for STAT5 target sites on the *FRA2* gene was done using massive parallel sequencing (ChIP-Seq) data already available, which defines the genome-wide targets of STAT5A and STAT5B in CD4+ T cells. The data is available via the Gene Expression Omnibus (GEO), accession number GSM671400 and GSM671402 at www.ncbi.nlm.nih.gov/geo. Peaks for STAT5b binding to a region within intron 3 of the *FRA2* gene was observed at chr2:28,485,399-28,485,970 on the UCSC genome browser (Human Mar. 2006 (NCBI36/hg18) Assembly). This region is located close to GAS1 identified in this study which maps to the genome base position of Chr2:28,487,132-28,487,836. The site identified by the ChIP-seq study and the present study are almost 1200 bp away from each other and it is possible that DNA binding sites were juxtaposed by DNA looping to functionally interact and orchestrate transcriptional activation.

FRA2 is expressed in activated CD4+ T cells and is regulated by IL-2

To investigate whether IL-2 can induce *FRA2* gene expression, CD4 T cells were preactivated with PHA to achieve maximal IL-2




Figure 7. TCR induced FRA2 expression is dependent on IL-2 signaling. CD4+ T cells were TCR activated \pm HAT (humanized anti-Tac antibody) treatment and mRNA was prepared pre- and 17 hours post-stimulation. qRT-PCR analysis for FRA2 expression was carried out. TCR activation induces FRA2 expression, which is abrogated by the addition of HAT, indicating that IL-2R function is essential for induction of FRA2. This is representative of at least three independent experiments performed in triplicate.

doi:10.1371/journal.pone.0090370.g007

responsiveness by expressing the high affinity IL-2 receptor, followed by treatment with IL-2 for various times (2–24 hours) or left untreated before RNA was extracted and *FRA2* expression was analysed by quantitative real-time PCR (qRT-PCR). These studies revealed that *FRA2* is induced in a biphasic manner by IL-2 in activated CD4 T cells: with peak expression at approximately 4 hours, decreasing to basal levels within 12 hours and with a second peak at 24 hours (Figure 6). Thus, exogenous IL-2 alone efficiently stimulates *FRA2* expression in the presence of TCR stimulation.

TCR plus CD28-mediated induction of FRA2 is dependent on IL-2R signaling

To dissect the contribution of IL-2 receptor signaling to the TCR-induced expression of *FRA2*, the effect of clinically-




Figure 8. Activation of the JAK3-STAT5 pathway is essential for the induction of FRA2 gene expression by TCR activation. CD4+ T cells were stimulated via the TCR \pm the JAK3 inhibitor R333, RNA was prepared four hours post treatment. qRT-PCR analysis was performed to detect the relative expression of FRA2. FRA2 gene expression was induced by TCR activation and abrogated by R333 treatment. Shown is a representative experiment performed in triplicate and repeated three times.

doi:10.1371/journal.pone.0090370.g008




Figure 9. Transcriptional activities of the GAS1 sequence: Trimerised GAS1-luciferase reporter was cotransfected with IL-2R components in 293T cells, as described in materials and methods. The results are from three independent experiments performed in triplicate. This shows that the GAS1 sequence identified by the ChIP studies can be specifically activated by STAT5 in an IL-2-receptor reconstitution assay in 293T cells.
doi:10.1371/journal.pone.0090370.g009

important inhibitors of CD25 and JAK3 on this process were examined. Cells were stimulated with anti-CD3 and anti-CD28 antibody, for specific T cell receptor activation which leads to IL-2 production. The human interleukin 2 receptor alpha (IL2R α) is also known as CD25 and HAT blocks IL-2 signalling. Human CD4+ T cells were isolated from buffy coats and stimulated with anti-CD3 and anti-CD28 antibodies for 17 hours in the presence or absence of humanized anti-Tac (HAT) antibody (Daclizumab, anti-CD25). It has previously been shown that HAT treatment efficiently blocks JAK3/STAT5 activation and consequent production of Th1 and Th2 cytokines following anti-CD3 and anti-CD28 antibody stimulation of PBMC [46]. Here TCR activation induced *FRA2* expression 17 hours after stimulation, which was abolished in the presence of HAT. Thus, the TCR induced activation of *FRA2* is dependent on IL-2/IL-2R signaling (Figure 7).

To confirm that induction of *FRA2* by T cell activation was specifically due to the activation of the JAK3/STAT5 pathway, a JAK3 inhibitor R333 [47], was employed during TCR activation. CD4 T cells were purified and stimulated with anti-CD3 and anti-CD28 antibodies in the presence or absence of R333. RNA was prepared from the samples and analysed by real-time PCR for *FRA2* expression. The data showed that TCR-mediated activation of CD4 T cells induced *FRA2*, 17 hours post stimulation, which was abrogated in the presence of the JAK3 inhibitor (Figure 8). Taken together, the data indicate that TCR-induced upregulation of *FRA2* gene expression is dependent on IL-2-signaling in CD4 T cells.

STAT5 binding site, GAS1 exerts regulatory activities

To confirm that the GAS1 sequence can induce STAT5-dependent transcriptional activity, a luciferase reporter assay was performed using an IL-2R reconstitution system, as previously described [18]. These studies revealed that IL-2-induced luciferase

expression from a GAS1 driven reporter construct could be activated by transfection of STAT5a or STAT5b alone when compared to the empty vector transfected negative control, which shows no IL-2 inducible transcriptional activation of luciferase activity (Figure 9). Interestingly, consistent with the ChIP-PCR results, STAT5b was able to induce higher levels of luciferase activity as compared to STAT5a. Co-expression of STAT5a and STAT5b did not significantly differ from the results obtained with either STAT5a and STAT5b alone. These data confirm those from previous studies on optimal GAS binding sites for STAT5, which reveal a favoured consensus sequence of TTC(C/T)N(G/A)GAA [23,48,49], as in GAS1 and are also consistent with the relative STAT5 binding enrichment for the two GAS motifs by ChIP (Figure 4C). Taken together the findings show that IL-2 induces specific STAT5 binding and transcriptional activation from an intronic GAS motif of the *FRA2* gene.

Conclusion

In this study, ChIP was used to generate a library of STAT5 regulated genes from activated human CD4 T cells stimulated with IL-2. Analysis of 105 putative STAT5 binding sites isolated, for their location with respect to TSS of genes, showed that the majority of the sites mapped to introns and intergenic regions, which is consistent with the findings of whole genome analysis of DNase-1 hypersensitive sites [50]. Although the consensus GAS recognition motif for dimeric STAT5 binding is TTCN₃GAA [23], a large proportion of the sites contained the more general consensus TTN₅AA. Gene annotation studies predicted a number of cellular functions regulated by STAT5, many of which were previously known but also exposed novel functions such as those related to metabolism and transport. The main disease prediction from the analysis of these STAT5-target genes is cancer, which correlates with previous studies of malignancies [51,52,53,54].

FRA2 is an example of one such tumor associated gene, whose regulation by STAT5 was studied here. The intronic STAT5 binding site in *FRA2* contained a consensus motif, TTCN₃GAA and was located in an architectural region of chromatin that is poised for transcriptional activation. Previous studies have shown that *FRA2* is expressed at the protein level during early Th2 cell polarization [11], and that *FRA2* is a putative STAT5 target gene [39]. Our studies extend these observations to reveal that the *FRA2* locus is in a poised chromatin state, enabling expression early during T cell activation in an IL-2 dependent manner. Interestingly, IL-2/STAT5, like *FRA2* is known to inhibit Th17 differentiation, and therefore the characterization of *FRA2* as a STAT5 target gene in this study may be one mechanism by which STAT5 can negatively regulate TH17 differentiation. Its role in T cell differentiation needs to be studied further.

Supporting Information

Table S1 Mapping of STAT5 ChIP clones. Clones obtained from the libraries were mapped using to their Chromosomal location using the UCSC genome browser.
(XLSX)

Author Contributions

Conceived and designed the experiments: AR STJ SUJ. Performed the experiments: AR RG MR. Analyzed the data: AR STJ SUJ. Contributed reagents/materials/analysis tools: STJ SUJ. Wrote the paper: AR STJ SUJ.

References

- Stark GR, Darnell JE, Jr. (2012) The JAK-STAT pathway at twenty. *Immunity* 36: 503–514.
- Gatzka M, Pickorz R, Moriggl R, Rawlings J, Ihle JN (2006) A role for STAT5A/B in protection of peripheral T-lymphocytes from postactivation apoptosis: insights from gene expression profiling. *Cytokine* 34: 143–154.
- Nagy ZS, LeBaron MJ, Ross JA, Mitra A, Rui H, et al. (2009) STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. *Mol Cancer* 8: 67.
- Liao W, Schones DE, Oh J, Cui Y, Cui K, et al. (2008) Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression. *Nat Immunol* 9: 1288–1296.
- Nagy ZS, Ross JA, Rodriguez G, Balint BL, Szeles L, et al. (2013) Genome wide mapping reveals PDE4B as an IL-2 induced STAT5 target gene in activated human PBMCs and lymphoid cancer cells. *PLoS One* 8: e57326.
- Nelson EA, Walker SR, Alvarez JV, Frank DA (2004) Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. *J Biol Chem* 279: 54724–54730.
- LeBaron MJ, Xie J, Rui H (2005) Evaluation of genome-wide chromatin library of Stat5 binding sites in human breast cancer. *Mol Cancer* 4: 6.
- Bell BD, Kitajima M, Larson RP, Stoklasek TA, Dang K, et al. (2013) The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses. *Nat Immunol* 14: 364–371.
- Yamane H, Zhu J, Paul WE (2005) Independent roles for IL-2 and GATA-3 in stimulating naive CD4+ T cells to generate a Th2-inducing cytokine environment. *J Exp Med* 202: 793–804.
- Rani A, Afzali B, Kelly A, Tewolde-Berhan L, Hackett M, et al. (2011) IL-2 regulates expression of C-MAF in human CD4 T cells. *J Immunol* 187: 3721–3729.
- Lund RJ, Loytomaki M, Naumanen T, Dixon C, Chen Z, et al. (2007) Genome-wide identification of novel genes involved in early Th1 and Th2 cell differentiation. *J Immunol* 178: 3648–3660.
- Ciofani M, Madar A, Galan C, Sellars M, Mace K, et al. (2012) A validated regulatory network for Th17 cell specification. *Cell* 151: 289–303.
- Foletta VC (1996) Transcription factor AP-1, and the role of Fra-2. *Immunol Cell Biol* 74: 121–133.
- Nishina H, Sato H, Suzuki T, Sato M, Iba H (1990) Isolation and characterization of fra-2, an additional member of the fos gene family. *Proc Natl Acad Sci U S A* 87: 3619–3623.
- Nakayama T, Higuchi T, Oiso N, Kawada A, Yoshie O (2012) Expression and function of FRA2/JUND in cutaneous T-cell lymphomas. *Anticancer Res* 32: 1367–1373.
- Crawford GE, Holt IE, Mullikin JC, Tai D, Blakesley R, et al. (2004) Identifying gene regulatory elements by genome-wide recovery of DNase hypersensitive sites. *Proceedings of the National Academy of Sciences of the United States of America* 101: 992–997.
- Mi H, Muruganujan A, Thomas PD (2013) PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. *Nucleic Acids Res* 41: D377–386.
- John S, Vinkemeier U, Soldaini E, Darnell JE, Jr., Leonard WJ (1999) The significance of tetramerization in promoter recruitment by Stat5. *Mol Cell Biol* 19: 1910–1918.
- Wang Q, Carroll JS, Brown M (2005) Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. *Mol Cell* 19: 631–642.
- Robertson G, Hirst M, Bainbridge M, Bilenyk M, Zhao Y, et al. (2007) Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. *Nat Methods* 4: 651–657.
- Martone R, Euskirchen G, Bertone P, Hartman S, Royce TE, et al. (2003) Distribution of NF-kappaB-binding sites across human chromosome 22. *Proc Natl Acad Sci U S A* 100: 12247–12252.
- Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. *Nat Genet* 38: 1289–1297.
- Soldaini E, John S, Moro S, Bollenbacher J, Schindler U, et al. (2000) DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. *Mol Cell Biol* 20: 389–401.
- Iyer VR, Horak CE, Scafe CS, Botstein D, Snyder M, et al. (2001) Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF. *Nature* 409: 533–538.
- Lin JX, Li P, Liu D, Jin HT, He J, et al. (2012) Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. *Immunity* 36: 586–599.
- Moriggl R, Sexl V, Kenner L, Dutsch C, Stangl K, et al. (2005) Stat5 tetramer formation is associated with leukemogenesis. *Cancer Cell* 7: 87–99.
- Greif PA, Eck SH, Konstantin NP, Benet-Pages A, Ksienzyk B, et al. (2011) Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. *Leukemia* 25: 821–827.
- Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. *Nat Rev Cancer* 4: 177–183.
- Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, et al. (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat Genet* 43: 830–837.
- Pleasant ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, et al. (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* 463: 191–196.
- Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 455: 1069–1075.
- Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 321: 1801–1806.
- Stransky N, Eglhoff AM, Tward AD, Kostic AD, Cibulskis K, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. *Science* 333: 1157–1160.
- Berger MF, Lawrence MS, Demicheli F, Drier Y, Cibulskis K, et al. (2011) The genomic complexity of primary human prostate cancer. *Nature* 470: 214–220.
- Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. *Science* 318: 1108–1113.
- Clark MJ, Homer N, O'Connor BD, Chen Z, Eskin A, et al. (2010) U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. *PLoS Genet* 6: e1000832.
- Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, et al. (2011) High-resolution characterization of a hepatocellular carcinoma genome. *Nat Genet* 43: 464–469.
- Gui Y, Guo G, Huang Y, Hu X, Tang A, et al. (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. *Nat Genet* 43: 875–878.
- Rasche A, Johnston JA, Amati B (2003) Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. *Mol Cell Biol* 23: 4162–4173.
- Boyle AP, Davis S, Shulha HP, Meltzer P, Margulies EH, et al. (2008) High-resolution mapping and characterization of open chromatin across the genome. *Cell* 132: 311–322.
- Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, et al. (2007) High-resolution profiling of histone methylations in the human genome. *Cell* 129: 823–837.
- Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, et al. (2008) Combinatorial patterns of histone acetylations and methylations in the human genome. *Nat Genet* 40: 897–903.
- Berger SL (2007) The complex language of chromatin regulation during transcription. *Nature* 447: 407–412.
- Shahbazian MD, Grunstein M (2007) Functions of site-specific histone acetylation and deacetylation. *Annu Rev Biochem* 76: 75–100.
- Li B, Carey M, Workman JL (2007) The role of chromatin during transcription. *Cell* 128: 707–719.
- McDyer JF, Li Z, John S, Yu X, Wu CY, et al. (2002) IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. *J Immunol* 169: 2736–2746.
- Velotta JB, Deuse T, Haddad M, Masuda E, Park G, et al. (2009) A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection. *Transplantation* 87: 653–659.
- Ehret GB, Reichenbach P, Schindler U, Horvath CM, Fritz S, et al. (2001) DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. *J Biol Chem* 276: 6675–6688.
- Fung MM, Chu YL, Fink JL, Wallace A, McGuire KL (2005) IL-2- and STAT5-regulated cytokine gene expression in cells expressing the Tax protein of HTLV-1. *Oncogene* 24: 4624–4633.
- Crawford GE, Holt IE, Whittle J, Webb BD, Tai D, et al. (2006) Genome-wide mapping of DNase hypersensitive sites using massively parallel signature sequencing (MPSS). *Genome research* 16: 123–131.
- Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, et al. (2010) Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. *EMBO Mol Med* 2: 98–110.
- Barash I (2012) Stat5 in breast cancer: potential oncogenic activity coincides with positive prognosis for the disease. *Carcinogenesis* 33: 2320–2325.
- Ferbeyre G, Moriggl R (2011) The role of Stat5 transcription factors as tumor suppressors or oncogenes. *Biochim Biophys Acta* 1815: 104–114.
- Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer* 9: 798–809.